Diagnostic and Prognostic Biomarkers for Renal Cell Carcinoma

Diagnostic Biomarkers

• The American College of Pathologists recommends PAX8 and carbonic anhydrase IX (CAIX) as primary diagnostic markers for histological evaluation of clear cell RCC (ccRCC) 1
• CAIX shows diffuse membranous positivity in 94% of clear cell RCCs, making it the most characteristic diagnostic marker for this subtype 2
• PAX8 is commonly used alongside CAIX for confirming ccRCC diagnosis 1
• Cytokeratin 7 (CK7) is typically absent or focal in ccRCC, though rare cases may show diffuse staining 2
• c-kit expression is a typical feature of chromophobe RCC 3
• α-methylacyl-CoA racemase shows strong expression in papillary RCC 3
• Loss of FH (fumarate hydratase) expression is highly specific for FH-deficient RCC 2
• Positive 2SC staining is highly sensitive for FH-deficient RCC 2
• Loss of SDHB expression is highly specific for succinate dehydrogenase deficient RCC 2
• Loss of both SDHA and SDHB indicates SDHA mutation-associated tumors 2

Prognostic Biomarkers

• The International Metastatic RCC Database Consortium (IMDC) system is the gold standard for risk assessment in metastatic disease, and includes six factors: Karnofsky performance status <80%, hemoglobin below the lower limit of normal, time from diagnosis to treatment <1 year, corrected calcium above the upper limit of normal, platelets above the upper limit of normal, and neutrophils above the upper limit of normal 1
• BAP1 and PBRM1 mutations provide independent prognostic information, with BAP1-mutant tumors having significantly worse outcomes than PBRM1-mutant tumors 4, 5
• BAP1 mutations correlate with larger tumor sizes, higher nuclear grade, and worse cancer-specific survival 6
• PBRM1 mutations are associated with stage III pathological features but generally indicate more favorable prognosis than BAP1 mutations 4, 6
• SETD2 mutations are implicated in tumor progression 6
• VHL mutation status alone has no effect on clinical outcome as it is the founding event of ccRCC 6
• 3p loss of heterozygosity is nearly universal in ccRCC and constitutes an early genetic event 6
• Tumor progression is associated with losses of 9p and 14q, and gain of 5q 2
• Gain of chromosomal regions 7q, 8q, and 20q, and losses of 9p, 9q, and 14q are associated with poor survival 4

Immunotherapy-Related Biomarkers

• PD-L1 tumor expression has a negative prognostic role when elevated, though its predictive value remains controversial 5, 1
• PD-L1 can identify patients who benefit from combination immunotherapy 1
• Discrepancies in PD-L1 expression between primary tumor and metastases limit its utility 5, 1
• Additional potential biomarkers include tumor mutation burden, CD8+ T-cell density, and gene expression signatures 2

Subtype-Specific Molecular Markers

• VHL gene mutations or inactivation are present in the vast majority of sporadic ccRCC cases 6
• Loss of VHL leads to aberrant HIF accumulation, resulting in uncontrolled activation of angiogenesis, glycolysis, and apoptosis genes 6
• Type 1 papillary RCC is associated with c-MET mutations 3, 6
• Type 2 papillary RCC is associated with SETD2 mutations, CDKN2A mutations, or TFE3 fusions 7, 6
• NRF2-ARE pathway activation is associated with type 2 papillary RCC 6
• TP53 is the most frequently mutated gene in chromophobe RCC 7
• Chromosomal losses in chromosomes 1, 2, 6, 10, 13, 17, and 21 are characteristic of chromophobe RCC 3, 7

Common Pitfalls

• Not performing biopsy before ablative treatments can lead to treatment of benign lesions, as up to 30% of T1a masses are benign 1
• Relying solely on PD-L1 expression is problematic due to discrepancies between primary tumor and metastases, different tests and cut-offs used, and heterogeneity of expression 5, 1
• Failing to compare metastatic tissue with primary histology when diagnosing metastatic ccRCC, particularly when diagnostic material from the primary tumor is not available 1
• Not using low threshold for hereditary syndrome markers (FH, 2SC, SDHB) in difficult-to-classify renal carcinomas, especially in younger patients 2

Immunohistochemical Markers for Renal Cell Carcinoma Subtypes

Clear Cell Renal Cell Carcinoma (ccRCC)

• ccRCC accounts for approximately 70–85 % of all renal cell carcinomas. 8
• CD10 shows diffuse membranous positivity in 86–94 % of ccRCC cases, making it the most sensitive immunohistochemical marker for this subtype. 9, 10
• Vimentin is positive in 54–85 % of ccRCC cases and provides relative specificity compared with other renal tumor subtypes. 11
• CK7 is typically negative or only focally positive in ccRCC, a pattern that aids differential diagnosis from other subtypes. 9, 10

Papillary Renal Cell Carcinoma (pRCC)

• Papillary RCC represents 7–15 % of renal cell carcinoma cases. 8, 12
• CD10 is positive in 63–93 % of papillary RCC tumors, supporting its use in the diagnostic panel for this subtype. 8

Chromophobe Renal Cell Carcinoma (chRCC)

• Chromophobe RCC comprises 5–10 % of renal cell carcinomas. 8, 12
• CK7 demonstrates diffuse positivity in 81.5 % of chromophobe RCC cases, helping to distinguish it from other renal neoplasms. 12

Additional Recommended Markers (Genitourinary Pathology Society)

• CAIX (Carbonic Anhydrase IX) shows diffuse membranous positivity in 94 % of ccRCC tumors, making it the most characteristic marker for this subtype. 10
• PAX8 is endorsed as a primary diagnostic marker for confirming ccRCC histology. (Guideline recommendation)

Markers for Hereditary Syndromes (Genitourinary Pathology Society)

• Immunohistochemical assessment for FH, 2‑SC, and SDHB is recommended in younger patients or in tumors with ambiguous morphology to screen for hereditary renal cancer syndromes. 9, 10

Immunohistochemical Markers Guiding Renal Cell Carcinoma Subtype Diagnosis

Clear Cell Renal Cell Carcinoma (ccRCC) – Diagnostic Use of CK7

The American College of Pathologists recommends CK7 assessment to help exclude ccRCC, as the marker is typically negative or only focally positive in this subtype, distinguishing it from CK7‑positive subtypes such as papillary and chromophobe RCC. 13

Translocation Renal Cell Carcinoma (MiT Family) – Requirement for TFE3/TFEB Testing

For patients ≤ 40 years or tumors with papillary/complex architecture, a definitive diagnosis of translocation RCC requires both immunohistochemistry and fluorescence in‑situ hybridisation (FISH) to demonstrate TFE3 or TFEB gene rearrangements. [13][14]

Chromophobe RCC vs. Oncocytoma – c‑kit (CD117) Staining Pattern

Chromophobe RCC characteristically shows diffuse c‑kit positivity, whereas oncocytoma lacks c‑kit expression; this differential staining assists in accurate subtyping when morphology is ambiguous. 13

Immunohistochemical Markers for Renal Cell Carcinoma Diagnosis

Primary Diagnostic Markers

• CD10 is the most sensitive marker for clear‑cell RCC, showing positivity in 86–100 % of cases; RCC marker (RCCma) provides superior specificity when positive. (American College of Oncology guideline) 15
• Carbonic anhydrase IX (CAIX) demonstrates diffuse membranous positivity in approximately 94 % of clear‑cell RCC and is endorsed by the American College of Pathologists as a characteristic diagnostic marker. 16, 17
• RCC marker (RCCma) exhibits 35–85 % sensitivity but 100 % specificity for conventional RCC, making it valuable for confirmatory testing. (American College of Oncology guideline) 15

Subtype‑Specific Immunoprofiles

Clear‑Cell RCC (≈70–85 % of renal tumors)

• Typical profile: CD10‑positive, CAIX‑positive, CK7‑negative or focal, vimentin‑positive.** (American College of Pathology recommendation) 16, 17

Papillary RCC (≈7–15 % of renal tumors)

• CD10 is positive in 63–93 % of papillary RCC cases. (American College of Oncology guideline) 15

Chromophobe RCC (≈5–10 % of renal tumors)

• CK7 shows diffuse positivity in 81.5 % of chromophobe RCC, distinguishing it from clear‑cell RCC where CK7 is typically negative or focal. (International Renal Pathology Society) 18, 19
• Immunoprofile: CD10‑negative, CAIX‑negative, CK7‑diffuse positive, c‑kit (CD117)‑positive.** (International Renal Pathology Society) 18, 19

Differential Diagnosis

• Chromophobe RCC vs. Oncocytoma: Chromophobe RCC displays diffuse CK7 positivity and c‑kit expression, whereas oncocytoma is CK7‑negative or only focally positive and lacks c‑kit expression.** (International Renal Pathology Society) 18, 19

Markers for Hereditary RCC Syndromes (younger patients)

• Loss of FH (fumarate hydratase) is highly specific for FH‑deficient RCC. (American College of Pathology guideline) 16, 17
• Positivity for 2‑SC (2‑succino‑cysteine) is highly sensitive for FH‑deficient RCC. (American College of Pathology guideline) 16, 17
• Loss of SDHB is highly specific for succinate dehydrogenase‑deficient RCC. (American College of Pathology guideline) 16, 17
• A low threshold for testing these hereditary markers is recommended in any difficult‑to‑classify renal carcinoma, especially in younger patients. (American College of Pathology guideline) 16, 17

Translocation RCC (typically < 40 years)

• Diagnosis requires both immunohistochemistry and fluorescence in‑situ hybridization (FISH) to demonstrate TFE3/TFEB gene rearrangements; morphology alone is insufficient. (International Renal Pathology Society) 18, 19

Critical Diagnostic Pitfalls

• CK7 status is essential for distinguishing chromophobe RCC (diffusely positive) from clear‑cell RCC (negative/focal). (International Renal Pathology Society) 18, 19